ABSTRACT: Atypical antipsychotics have become the mainstay of therapy for psychosis. Though extrapyramidal side effects have been reduced with atypical antipsychotics, yet there are increased concerns over metabolic effects. The present study is aimed to comparatively evaluate the metabolic profile of olanzapine and iloperidone in cases of psychosis. A prospective, randomized, open label, observational study of 6 months duration was conducted in the Department of Pharmacology and Department of Psychiatry, Rohilkhand Medical College and Hospital, Bareilly. A total of 62 patients of both sexes newly diagnosed with psychosis (ICD-10, F20-F29) were included in the study, 31 each in olanzapine and iloperidone groups. Demographic parameters were recorded, following which the patient's body weight, BMI, fasting blood sugar and lipid profile were estimated at baseline. Follow-up of the patients was done periodically after one month, three months and six months. Olanzapine treated patients showed markedly significant rise in body weight up to 7 kg at the endpoint (p<0.0001) at each follow-up, with a significant increase in BMI. Rise in fasting blood sugar (FBS), total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL) levels werealso statistically significant. At the same time, significant decrease in HDL levels was also observed. Iloperidone treated patients showed statistically significant less rise in body weight (upto 1kg, p<0.05) and BMI. No significant changes in fasting blood sugar, total cholesterol, LDL and HDL levels were noted, while TG levels were significantly reduced. Iloperidone caused numerically less rise in bodyweight and BMI, and fewer metabolic adverse effects as compared to olanzapine, and hence should be preferred.
disorders, induced delusional disorder and schizoaffective disorders.
2
Psychosis is primarily treated with antipsychotic drugs. Antipsychotic drugs are classified as typical and atypical agents. Atypical antipsychotic agents, in addition to their moderate potencies at dopamine receptors, interact with varying affinities at several other classes of receptors like alpha1 and alpha2 adrenergic, 5-HT1A, 5-HT2A, 5-HT2C, M and H1. 3 The clinically effective doses of atypical antipsychotics compared with typical antipsychotic exhibit markedly reduced extrapyramidal symptoms risk. 3 Atypical antipsychotics possess the advantage of treating negative symptoms. Yet there have been increased concerns over metabolic effects like weight gain, hyperglycemia, diabetes mellitus and lipid abnormalities.
3
A comparative evaluation between olanzapine versus iloperidone has not been investigated thoroughly. A few studies have assessed the adverse effect profile of olanzapine with iloperidone, though not in an Indian population. The aims of the present study were to comparatively evaluate olanzapine (OLZ) which is a more commonly used antipsychotic for the treatment of psychosis with iloperidone (ILO) with regard to metabolic profile and assess whether there exists any major advantage of one drug over the other for the Indian population.
METHODOLOGY
A prospective, randomized, observational study of 6months duration (October 2013 to March 2014) was conducted to comparatively evaluate the metabolic safety profile of iloperidone versus olanzapine in the departments of pharmacology and psychiatry of Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh. Approval for the study protocol was obtained from the institutional ethics committee. The CTRI registration number of the study is CTRI/2014/10/005144. Each subject signed an informed consent form and could withdraw without prejudice at any time. Patients 18-65 years and of both genders attending the psychiatry outpatient department during the study period diagnosed with psychosis falling under the group (F20-F29) as per ICD-10 criteria and prescribed monotherapy with olanzapine or iloperidone were eligible to participate in the study. The exclusion criteria included history of diabetes mellitus, severe cardiovascular disease, hepatic, renal or untreated thyroid disease, current medication such as antiepileptics (valproate or carbamazepine), antiparkinsonian agents (levodopa), birth control pills, steroids, propranolol and thiazide diuretics and agents that induce weight loss, pregnancy or breast-feeding and irregular compliance. A total of 62 patients (OLZ=31 and ILO=31) comprised the sample; of these two patients dropped out of the olanzapine group (n= 29) due to extrapyramidal side effects. All patients were allotted a reference number; the odd numbers were assigned to the olanzapine and even numbers to the iloperidone group. A predesigned, structured and pretested questionnaire was used to collect demographic information. A complete clinical examination was conducted on all study subjects to rule out any chronic ailments referred to in the exclusion criteria. Data regarding age, sex, socio-economic status, family history, and other demographic parameters were recorded. For calculating BMI, the patient's height and weight were recorded. Blood pressure was measured using a standard protocol. Other relevant investigations were also performed. The patient's bodyweight (BW), body mass index BMI, fasting blood sugar (FBS) and lipid profile (TC, LDL, TG, HDL) was estimated at baseline and on each subsequent follow-up. Flexible doses of both iloperidone (8-12 mg/day) and olanzapine (10- 2 ) overtime with iloperidone treatment (p<0.05 after 6 months). However, there were no significant alterations (p>0.05) between the baseline values and follow-up values of FBS, TC, LDL and HDL. Only TG showed a statistically significant decrease (p<0.05) after one, three and six months. Table 4 shows the comparative values of BW and BMI between olanzapine and iloperidone in followups. The two groups were well matched at baseline (p>0.05). After one month, treatment bodyweight showed no significant change (p=0.1179). After three months, the olanzapine group showed a statistically significant increase in bodyweight (p=0.0109) and bodyweight recorded a further more significant rise (p=0.0006) after six months. In short, olanzapine showed an increase of approximately 7kg over six months compared to 1kg with iloperidone. Regarding BMI, there was comparatively no significant changes after one month and three months of therapy (p=0.9581 and p=0.1115, respectively). However, after 6 months there was markedly significant increase in BMI with olanzapine as compared to iloperidone (p=0.0025). Table 5 compares the alterations in FBS between olanzapine and iloperidone treated groups from baseline to one, three and six months. Both groups were comparable at baseline (p>0.05) and after 1 month (p>0.05). However after 3 months statistically marked significant increase in FBS (p = 0.0048, 88.72±7.41 mg/dl in olanzapine group versus 83.77±5.60 mg/dl in iloperidone) was noted, FBS after 6 months became statistically highly significant (p<0.0001, 92.90±1.72 mg/dl in the olanzapine group versus 83.90±5.34 mg/dl in the iloperidone group). Table 6 shows comparative changes in lipid profile between olanzapine versus iloperidone. Statistically no significant difference in LDL and HDL levels (p>0.05) was noted. Though, TC and TG levels were comparable at baseline after one month and three months (p>0.05), yet the olanzapine group showed statistically significant increase in TC (150± 24.68 mg/dl, p<0.05) and TG (134.41± 16.66 mg/dl, P<0.05) after six months. 
DISCUSSION
Workers in the field have documented that most atypical antipsychotic agents, except a few, cause significant rapid increase in bodyweight ranging from 2-14 kg which occurs within 12 weeks of treatment and is one of the important adverse effects leading to drop out from the study.
4-7
In the present study, a rapid markedly significant increase in bodyweight was noted with olanzapine, after one (p<0.0001) three (p<0.0001), and six months (p<0.0001) whereas iloperidone caused comparatively less increase in weight during similar periods. The mean change in weight from baseline to endpoint was 7kg with olanzapine compared to 1 kg with iloperidone. 12 have also noted that olanzapine and clozapine caused marked increase in weight. In a meta-analysis of 48 studies, Rummel-Kluge et al 13 have noted that olanzapine produced more weight gain than all other second generation antipsychotic agents. The results of the present study with respect to olanzapine are in line with previous findings. De Hert et al 14 in a meta-analysis observed statistically significant weight gain with iloperidone (p<0.001) greater than placebo. Cutler et al 15 in a 25-week clinical trial with iloperidone (12 mg BD) noted weight gain (9.2%). Weiden et al 16 observed that iloperidone caused a mild weight increase (1.5-2.1 kg) similar to risperidone (1.5kg). Hochfeld et al 17 in a meta-analysis of 3200 patients who were administered iloperidone noted an average weight gain of about 2kg following treatment for greater than one year and most weight gain occurred within first six weeks of the studies. Thus, the results of the present study are comparable with these studies for iloperidone and that weight gain has been noticed after 1month of therapy (p=0.0019). The precise mechanism of weight gain due to atypical antipsychotics is not clearly understood and appears to be a multifactorial phenomenon involving basically effects on receptors and neuroendocrine pathways (hypothalamic neurotransmitters and neuropeptides). Serotonin enhances satiety by stimulating Proopiomelanocortin (POMC) secretion by an effect mediated by 5-HT2c receptors; antagonists of 5-HT2c receptors prevent or delay the onset of satiety, thereby increasing the size of the meal. Histamine H1 receptor blockade activates hypothalamic AMP-activated protein kinase (AMPK), increasing appetite. Additionally, D2 receptor antagonism has also been implicated in antipsychotic associated weight gain. Further cells in the arcuate nucleus of the hypothalamus express neuropeptide Y (NPY) and Agouti-related protein (AgRP), two highlyorexigenic (appetite enhancing) peptides whose expression is increased by ghrelin and inhibited by leptin.
18
In the present study we observed a highly significant increase in body mass index (BMI) after one, three and six months (p<0.0001) with olanzapine.
In contrast iloperidone caused statistically significant increase in BMI only after three (p=0.0089) and six months (p=0.0229). Thus, comparatively iloperidone has shown a lower and delayed increase in BMI than olanzapine. 23 also demonstrated that after one year of therapy, olanzapine use was a significant predictor of developing new onset diabetes and that development of diabetes mellitus takes more than 15 months.
In Phase I of the CATIE trial 5 , olanzapine was associated with a significant increase in mean HbA1c. Similar to weight gain, olanzapine and clozapine appear to have the greatest risk for diabetes. A significant association between olanzapine and diabetes mellitus and insulin resistance in olanzapine subjects has also been observed.
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De Hert et al 14 in a meta-analysis haveobserved significant changes in glucose levels during shortterm treatment with iloperidone (+ 6.90 mg/dl; 95% CI 2.4,11.8, p< 0.01). Hochfeld et al 17 observed fasting mean (SD) glucose changes with iloperidone 6.6 (24.0) from baseline to end of study, while Cutler et al 15 in a 25-week clinical trial with iloperidone noted that levels of serum glucose, lipids and prolactin were essentially unchanged or decreased during the treatment. Our observations in respect to FBS are in conformity with these authors. Atypical antipsychotics have been shown to cause dyslipidemia 27-28 . These changes are largely related to concomitant weight gain; therefore, agents associated with the greatest weight gain may have the greatest propensity to cause dyslipidemia 28 . In our study, changes in lipid metabolism were observed in both olanzapine and iloperidone groups. Olanzapine significantly altered lipid parameters (TC, TG, LDL and HDL). TC levels significantly increased from baseline to endpoint (p<0.0001). Initially TG levels did not change till one month but rose significantly after three months (p<0.0001) and six months (p<0.0001). LDL values also increased significantly after each follow up. Cardioprotective HDL levels significantly decreased after three months (p<0.05) and six months (p<0.0001): these findings are similar to those of other workers who have also documented similar change in lipid metabolism with olanzapine. Lindenmayer et al 21 observed significant increase in mean TC at 14 weeks of 20.1mg/dl (p<0.002) in patients taking olanzapine. Atmaca et al 12 observed that olanzapine produced more changes in TC than risperidone, aripiprazole and ziprasidone besides there beinga marked increase in serum TG and leptin levels. Previous studies have documented a relation between atypical antipsychotics clozapine and olanzapine and serum leptin levels. Leptin has been associated with atypical antipsychotic induced weight gain. Besides, atypical antipsychotics especially clozapine and olanzapine are associated with higher risk of metabolic syndrome.
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Iloperidone however, showed no significant changes in TC, LDL, HDL levels from baseline to endpoint of therapy. An interesting result observed in this study was that TG levels were significantly decreased with iloperidone after one (P<0.05), three (P=0.001) and six months (P<0.05). Hochfeld et al 17 observed that non-fasting cholesterol showed decrease from baseline to time points after 4 weeks and neither short term nor long term treatment with iloperidone led to development of high or borderline high cholesterol in the overall study population. Fasting mean (SD) triglycerides changes were -0.83(82.3) mg/dl. Thus, iloperidone showed small changes in lipids that are unlikely to be of clinical concern. A decrease in TG levels is in line with our observations. Limitations of the present study include the following: First, as the duration of the present study was relatively short, it was not possible to elicit further changes in bodyweight, BMI, glucose levels and lipid profile. Second, the number of patients included was small.
CONCLUSION
Comparative data are still too sparse to evaluate the metabolic safety profile of the two drugs used. Thus, there is a clear need for further controlled studies to comparatively evaluate which of the two agents is less problematic for short term safety and tolerability for treatment, with respect to weight gain and metabolic disturbances. Our study supports the safety and tolerability of iloperidone over olanzapine for the treatment of psychosis.
